Abstract

ObjectiveTo evaluate active inflammatory lesions (AIL) and structural changes (SC) in patients with active non-radiographic axial spondyloarthritis (nr-axSpA) compared with patients with ankylosing spondylitis (AS) on whole-body MRI (wb-MRI).Method75 patients...

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
SAT0272 Whole body MRI in active non-radiographic axial spondyloarthritis and ankylosing spondylitis – distribution of findings in the axial skeleton
K.G Hermann ... B Hamm
Annals of the Rheumatic Diseases | VOL. 71
K.G Hermann, et. al.K.G Hermann ... B Hamm
01 Jun 2013
Consensus statements on the imaging of axial spondyloarthritis in Australia and New Zealand.
Steven L Truong ... Stephen Stuckey
Journal of Medical Imaging and Radiation Oncology | VOL. 61
Steven L Truong, et. al.Steven L Truong ... Stephen Stuckey
19 Dec 2016
AB0870 Whole body MRI findings of non axial manifestations in early axial spondyloarthritis – results of the esther trial at baseline
C.E Althoff ... J Sieper
Annals of the Rheumatic Diseases | VOL. 71
C.E Althoff, et. al.C.E Althoff ... J Sieper
01 Jun 2013
Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial
I-H Song ... H Haibel
Annals of the Rheumatic Diseases | VOL. 70
I-H Song, et. al.I-H Song ... H Haibel
01 Apr 2011
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
Expert consensus recommendations for the diagnosis and treatment of chronic non-bacterial osteitis (CNO) in adults
Elizabeth M Winter ... Anne T Leerling
Annals of the Rheumatic Diseases | VOL. -
Elizabeth M Winter, et. al.Elizabeth M Winter ... Anne T Leerling
28 Nov 2024
Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial
Jinjing Liu ... Xiaofeng Zeng
Annals of the Rheumatic Diseases | VOL. -
Jinjing Liu, et. al.Jinjing Liu ... Xiaofeng Zeng
27 Nov 2024
CD-19 CAR-T cells for polyrefractory rheumatoid arthritis
Merav Lidar ... Abraham Avigdor
Annals of the Rheumatic Diseases | VOL. -
Merav Lidar, et. al.Merav Lidar ... Abraham Avigdor
27 Nov 2024
Correction: Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment
-
Annals of the Rheumatic Diseases | VOL. -
--
27 Nov 2024
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.